Please login to the form below

Not currently logged in
Email:
Password:

Encouraging data for Roche flu drug ahead of FDA decision

Trial looks at benefts in high risk groups

Roche has produced promising phase 3 data for its first-in-class influenza treatment in patients who are at a high risk for complications.

Baloxavir marboxil is a single-dose, investigational oral medicine, and has just achieved its primary endpoint in the CAPSTONE-2 trial comparing it with placebo and Tamiflu.

Tamiflu was a multi-billion dollar earner just a few years ago, but generic versions have now flooded onto the market.

The new treatment could be an advance on Tamiflu, showing efficacy in high risk groups where the older drug had not. Additionally, the candidate also comes in the form of a single pill, unlike Tamiflu, which needs to be administered twice a day for five days.

The CAPSTONE-2 trial showed that baloxavir marboxil significantly reduced time in improvement of influenza symptoms versus placebo in people at high risk of serious complications from flu, which included adults 65 years of age or older, or those who have conditions such as asthma, chronic lung disease, morbid obesity, or heart disease.

Tamiflu

The pipeline drug will have to significantly outperform the now generic Tamiflu to gain traction

The new data comes just ahead of the FDA’s expected ruling on the drug, which is scheduled for 24 December. If approved, baloxavir marboxil will be the first single-dose oral antiviral, and the first medicine with a novel proposed mechanism of action to treat flu in nearly 20 years.

Discovered and developed by Shionogi, the drug is already approved in Japan and marketed as Xofluza, with Roche holding the marketing rights  outside Japan and Taiwan.

Baloxavir is the first in a new class of antivirals designed to inhibit the cap-dependent endonuclease protein within the influenza virus, preventing the virus from replicating in the body early in its lifecycle.

The phase 3 CAPSTONE-2 study showed baloxavir cut the median time of improvement to 73.2 hours versus 102.3 hours in patients on placebo.

The trial also showed the drug was well-tolerated and no new safety signals were identified, and these results will be presented as a late-breaking oral presentation during IDWeek 2018 in San Francisco, CA on Saturday 6 October 2018.

The drug is also to be studied in a phase 3 programme including paediatric patients and severely ill hospitalised patients with influenza.

Analysts say the new treatment will have to generate more evidence of significant benefits in these high risk groups in order for healthcare systems to switch away from generic oseltamivir.

Roche is in need of a new set of innovative products, as its older generation of blockbusters, Avastin, Herceptin and MabThera/Rituxan come under competition from biosimilars.

Article by
Andrew McConaghie

4th October 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics